25 XP   0   0   10

GlycoMimetics Inc
Buy, Hold or Sell?

Let's analyse Glycomimetics together

PenkeI guess you are interested in GlycoMimetics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of GlycoMimetics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about GlycoMimetics Inc

I send you an email if I find something interesting about GlycoMimetics Inc.

Quick analysis of Glycomimetics (30 sec.)










What can you expect buying and holding a share of Glycomimetics? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.60
Expected worth in 1 year
$0.53
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
$-0.07
Return On Investment
-3.8%

For what price can you sell your share?

Current Price per Share
$1.84
Expected price per share
$1.74 - $3.38
How sure are you?
50%

1. Valuation of Glycomimetics (5 min.)




Live pricePrice per Share (EOD)

$1.84

Intrinsic Value Per Share

$-5.85 - $-2.82

Total Value Per Share

$-5.26 - $-2.22

2. Growth of Glycomimetics (5 min.)




Is Glycomimetics growing?

Current yearPrevious yearGrowGrow %
How rich?$38.4m$53.7m-$3.2m-6.4%

How much money is Glycomimetics making?

Current yearPrevious yearGrowGrow %
Making money-$9m-$16.3m$7.2m79.8%
Net Profit Margin-22,697.5%-9,741,071.6%--

How much money comes from the company's main activities?

3. Financial Health of Glycomimetics (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#503 / 1010

Most Revenue
#705 / 1010

Most Profit
#541 / 1010

Most Efficient
#967 / 1010

What can you expect buying and holding a share of Glycomimetics? (5 min.)

Welcome investor! Glycomimetics's management wants to use your money to grow the business. In return you get a share of Glycomimetics.

What can you expect buying and holding a share of Glycomimetics?

First you should know what it really means to hold a share of Glycomimetics. And how you can make/lose money.

Speculation

The Price per Share of Glycomimetics is $1.835. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Glycomimetics.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Glycomimetics, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.60. Based on the TTM, the Book Value Change Per Share is $-0.02 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.15 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Glycomimetics.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.14-7.7%-0.14-7.8%-0.18-9.9%-0.20-10.8%-0.15-8.3%
Usd Book Value Change Per Share-0.13-6.9%-0.02-1.0%-0.15-8.2%-0.13-7.1%0.010.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.13-6.9%-0.02-1.0%-0.15-8.2%-0.13-7.1%0.010.8%
Usd Price Per Share2.36-1.72-1.33-3.40-6.61-
Price to Earnings Ratio-4.18--3.04--1.95--4.16--10.02-
Price-to-Total Gains Ratio-18.68--10.34--12.70--25.71--30.75-
Price to Book Ratio3.96-2.35-1.76-2.01-5.40-
Price-to-Total Gains Ratio-18.68--10.34--12.70--25.71--30.75-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.835
Number of shares544
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.02-0.13
Usd Total Gains Per Share-0.02-0.13
Gains per Quarter (544 shares)-9.54-70.56
Gains per Year (544 shares)-38.15-282.25
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-38-480-282-292
20-76-860-564-574
30-114-1240-847-856
40-153-1620-1129-1138
50-191-2000-1411-1420
60-229-2380-1693-1702
70-267-2760-1976-1984
80-305-3140-2258-2266
90-343-3520-2540-2548
100-381-3900-2822-2830

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%2.038.00.05.0%5.041.01.010.6%
Book Value Change Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%8.032.00.020.0%10.035.02.021.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.047.00.0%
Total Gains per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%8.032.00.020.0%10.035.02.021.3%

Fundamentals of Glycomimetics

About GlycoMimetics Inc

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Fundamental data was last updated by Penke on 2024-04-11 09:59:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of GlycoMimetics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Glycomimetics earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Glycomimetics to the Biotechnology industry mean.
  • A Net Profit Margin of -90,790.0% means that $-907.90 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of GlycoMimetics Inc:

  • The MRQ is -90,790.0%. The company is making a huge loss. -2
  • The TTM is -22,697.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-90,790.0%TTM-22,697.5%-68,092.5%
TTM-22,697.5%YOY-9,741,071.6%+9,718,374.1%
TTM-22,697.5%5Y-2,466,228.6%+2,443,531.1%
5Y-2,466,228.6%10Y3,428,084.9%-5,894,313.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-90,790.0%-200.1%-90,589.9%
TTM-22,697.5%-216.8%-22,480.7%
YOY-9,741,071.6%-288.3%-9,740,783.3%
5Y-2,466,228.6%-449.1%-2,465,779.5%
10Y3,428,084.9%-605.5%+3,428,690.4%
1.1.2. Return on Assets

Shows how efficient Glycomimetics is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Glycomimetics to the Biotechnology industry mean.
  • -20.0% Return on Assets means that Glycomimetics generated $-0.20 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of GlycoMimetics Inc:

  • The MRQ is -20.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -16.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-20.0%TTM-16.2%-3.8%
TTM-16.2%YOY-27.4%+11.1%
TTM-16.2%5Y-14.8%-1.4%
5Y-14.8%10Y-11.9%-2.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-20.0%-13.3%-6.7%
TTM-16.2%-12.8%-3.4%
YOY-27.4%-11.7%-15.7%
5Y-14.8%-13.9%-0.9%
10Y-11.9%-15.7%+3.8%
1.1.3. Return on Equity

Shows how efficient Glycomimetics is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Glycomimetics to the Biotechnology industry mean.
  • -23.6% Return on Equity means Glycomimetics generated $-0.24 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of GlycoMimetics Inc:

  • The MRQ is -23.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -18.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-23.6%TTM-18.6%-5.1%
TTM-18.6%YOY-32.6%+14.1%
TTM-18.6%5Y-16.9%-1.6%
5Y-16.9%10Y-13.6%-3.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-23.6%-16.9%-6.7%
TTM-18.6%-16.1%-2.5%
YOY-32.6%-15.1%-17.5%
5Y-16.9%-19.3%+2.4%
10Y-13.6%-20.2%+6.6%

1.2. Operating Efficiency of GlycoMimetics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Glycomimetics is operating .

  • Measures how much profit Glycomimetics makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Glycomimetics to the Biotechnology industry mean.
  • An Operating Margin of -95,910.0% means the company generated $-959.10  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of GlycoMimetics Inc:

  • The MRQ is -95,910.0%. The company is operating very inefficient. -2
  • The TTM is -23,977.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-95,910.0%TTM-23,977.5%-71,932.5%
TTM-23,977.5%YOY-3,560,690.4%+3,536,712.9%
TTM-23,977.5%5Y-1,230,601.2%+1,206,623.7%
5Y-1,230,601.2%10Y4,076,568.7%-5,307,169.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-95,910.0%-296.2%-95,613.8%
TTM-23,977.5%-232.5%-23,745.0%
YOY-3,560,690.4%-298.2%-3,560,392.2%
5Y-1,230,601.2%-492.1%-1,230,109.1%
10Y4,076,568.7%-632.4%+4,077,201.1%
1.2.2. Operating Ratio

Measures how efficient Glycomimetics is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 960.10 means that the operating costs are $960.10 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of GlycoMimetics Inc:

  • The MRQ is 960.100. The company is inefficient in keeping operating costs low. -1
  • The TTM is 240.025. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ960.100TTM240.025+720.075
TTM240.025YOY36,320.842-36,080.817
TTM240.0255Y12,449.054-12,209.029
5Y12,449.05410Y-87,051.062+99,500.116
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ960.1003.231+956.869
TTM240.0253.310+236.715
YOY36,320.8423.890+36,316.952
5Y12,449.0545.739+12,443.315
10Y-87,051.0627.876-87,058.938

1.3. Liquidity of GlycoMimetics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Glycomimetics is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.41 means the company has $6.41 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of GlycoMimetics Inc:

  • The MRQ is 6.407. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.458. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.407TTM8.458-2.051
TTM8.458YOY6.394+2.064
TTM8.4585Y11.573-3.115
5Y11.57310Y13.553-1.980
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.4073.890+2.517
TTM8.4584.173+4.285
YOY6.3945.344+1.050
5Y11.5736.126+5.447
10Y13.5536.448+7.105
1.3.2. Quick Ratio

Measures if Glycomimetics is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Glycomimetics to the Biotechnology industry mean.
  • A Quick Ratio of 6.14 means the company can pay off $6.14 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of GlycoMimetics Inc:

  • The MRQ is 6.140. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.173. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.140TTM6.173-0.033
TTM6.173YOY6.205-0.033
TTM6.1735Y10.950-4.778
5Y10.95010Y13.151-2.200
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.1403.514+2.626
TTM6.1733.998+2.175
YOY6.2055.380+0.825
5Y10.9506.105+4.845
10Y13.1516.404+6.747

1.4. Solvency of GlycoMimetics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Glycomimetics assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Glycomimetics to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.15 means that Glycomimetics assets are financed with 15.2% credit (debt) and the remaining percentage (100% - 15.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of GlycoMimetics Inc:

  • The MRQ is 0.152. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.122. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.152TTM0.122+0.030
TTM0.122YOY0.155-0.033
TTM0.1225Y0.109+0.014
5Y0.10910Y0.100+0.009
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1520.339-0.187
TTM0.1220.336-0.214
YOY0.1550.271-0.116
5Y0.1090.366-0.257
10Y0.1000.389-0.289
1.4.2. Debt to Equity Ratio

Measures if Glycomimetics is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Glycomimetics to the Biotechnology industry mean.
  • A Debt to Equity ratio of 18.0% means that company has $0.18 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of GlycoMimetics Inc:

  • The MRQ is 0.180. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.140. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.180TTM0.140+0.040
TTM0.140YOY0.184-0.044
TTM0.1405Y0.123+0.017
5Y0.12310Y0.113+0.010
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1800.388-0.208
TTM0.1400.402-0.262
YOY0.1840.335-0.151
5Y0.1230.426-0.303
10Y0.1130.461-0.348

2. Market Valuation of GlycoMimetics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Glycomimetics generates.

  • Above 15 is considered overpriced but always compare Glycomimetics to the Biotechnology industry mean.
  • A PE ratio of -4.18 means the investor is paying $-4.18 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of GlycoMimetics Inc:

  • The EOD is -3.254. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.185. Based on the earnings, the company is expensive. -2
  • The TTM is -3.040. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.254MRQ-4.185+0.931
MRQ-4.185TTM-3.040-1.145
TTM-3.040YOY-1.945-1.094
TTM-3.0405Y-4.163+1.123
5Y-4.16310Y-10.020+5.857
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.254-2.264-0.990
MRQ-4.185-2.629-1.556
TTM-3.040-2.680-0.360
YOY-1.945-4.145+2.200
5Y-4.163-6.257+2.094
10Y-10.020-6.254-3.766
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of GlycoMimetics Inc:

  • The EOD is -3.879. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.989. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.381. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.879MRQ-4.989+1.110
MRQ-4.989TTM-3.381-1.608
TTM-3.381YOY-2.281-1.100
TTM-3.3815Y-5.016+1.635
5Y-5.01610Y-12.937+7.921
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.879-2.973-0.906
MRQ-4.989-3.333-1.656
TTM-3.381-3.553+0.172
YOY-2.281-5.605+3.324
5Y-5.016-8.376+3.360
10Y-12.937-8.865-4.072
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Glycomimetics is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.96 means the investor is paying $3.96 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of GlycoMimetics Inc:

  • The EOD is 3.076. Based on the equity, the company is fair priced.
  • The MRQ is 3.956. Based on the equity, the company is fair priced.
  • The TTM is 2.345. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.076MRQ3.956-0.880
MRQ3.956TTM2.345+1.611
TTM2.345YOY1.763+0.582
TTM2.3455Y2.010+0.335
5Y2.01010Y5.397-3.387
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.0761.896+1.180
MRQ3.9562.115+1.841
TTM2.3452.093+0.252
YOY1.7632.884-1.121
5Y2.0103.542-1.532
10Y5.3973.916+1.481
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of GlycoMimetics Inc.

3.1. Institutions holding GlycoMimetics Inc

Institutions are holding 53.544% of the shares of GlycoMimetics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Bvf Inc14.82750.3861954426200
2023-12-31Artal Group S A13.34350.6739858906400
2023-12-31NEA Management Company, LLC7.40180.7494476444000
2023-09-30Octagon Capital Advisors LP4.66060.6914300000000
2023-12-31Vanguard Group Inc3.76250.0001242186900
2023-12-31Goldman Sachs Group Inc2.85650.000418387101044216131.4316
2023-12-31AXA SA2.46590.01211587298-38400-2.3621
2023-12-31BlackRock Inc1.141807349832790.038
2023-12-31Acadian Asset Management LLC0.84070.0049541176-302875-35.8835
2023-12-31Geode Capital Management, LLC0.7440.0001478883190384.1401
2023-12-31GSA Capital Partners LLP0.31230.0399200993107208114.3125
2023-12-31Bridgeway Capital Management, LLC0.30640.011972002500014.518
2023-12-31State Street Corporation0.2901018676500
2023-12-31Two Sigma Advisers, LLC0.2570.0009165400-53600-24.4749
2023-12-31Connor Clark & Lunn Inv Mgmt Ltd0.22270.0016143359-5747-3.8543
2023-12-31Renaissance Technologies Corp0.19330.0005124444-76663-38.1205
2023-12-31Susquehanna International Group, LLP0.17320.00011114911114910
2023-12-31Northern Trust Corp0.17280.000111125450184.7234
2023-12-31Advisor OS, LLC0.15690.0311010001010000
2023-12-31MJP ASSOCIATES INC /ADV0.15690.06361010001010000
Total 54.28642.666134943591+1036965+3.0%

3.2. Funds holding GlycoMimetics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.98530.0004192233700
2024-02-29UTM IM GBP AXA Framlington Biotech2.36370.7867152209600
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.01250.00196520188310.1276
2024-01-31Fidelity Extended Market Index0.41910.002326985900
2023-12-31Bridgeway Ultra-Small Company Market0.29790.24361918002500014.988
2023-09-30BlackRock Extended Mkt Composite0.1910.001312296900
2024-02-29iShares Micro-Cap ETF0.18670.038112024300
2023-12-31BlackRock Extended Equity Market K0.16660.0018107280-216-0.2009
2023-12-31Franklin U.S. Small Cap Equity I0.14120.22599094100
2024-01-31Fidelity Total Market Index0.1260.00038116000
2024-02-29AXA IM Wave Biotech A Cap USD0.10060.794864793-1843-2.7658
2024-01-31Fidelity Series Total Market Index0.10010.00036445700
2024-02-29A&P Lifescience Fund A FI0.08573.03545517800
2024-02-29Vanguard Balanced Index Inv0.08530.00035490000
2023-12-31Northern Trust Extended Eq Market Idx0.06580.001742348769222.1953
2023-12-31NT Ext Equity Mkt Idx Fd - L0.06580.001742348769222.1953
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.06190.000239833-1541104-97.4804
2024-02-29Vanguard Instl Ttl Stk Mkt Idx InstlPls0.06190.00043983300
2024-01-31Spartan Total Market Index Pool E0.05480.0004352881337861.0589
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.05460.00133513700
Total 8.62655.13885554818-1488570-26.8%

3.3. Insider Transactions

Insiders are holding 3.046% of the shares of GlycoMimetics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-09-21Edwin RockBUY350001.38
2023-05-17Brian M HahnSELL37001.95
2023-05-10Daniel M JuniusBUY300001.56
2023-05-08Bruce S JohnsonBUY135001.57

4. Summary

4.1. Key Performance Indicators

The key performance indicators of GlycoMimetics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.126-0.018-86%-0.150+19%-0.130+3%0.014-1016%
Book Value Per Share--0.5970.784-24%0.834-28%1.619-63%1.525-61%
Current Ratio--6.4078.458-24%6.394+0%11.573-45%13.553-53%
Debt To Asset Ratio--0.1520.122+25%0.155-2%0.109+40%0.100+53%
Debt To Equity Ratio--0.1800.140+29%0.184-2%0.123+46%0.113+59%
Dividend Per Share----0%-0%-0%-0%
Eps---0.141-0.143+2%-0.181+29%-0.199+41%-0.153+8%
Free Cash Flow Per Share---0.118-0.135+15%-0.181+53%-0.179+51%-0.135+14%
Free Cash Flow To Equity Per Share---0.118-0.024-80%-0.148+26%-0.127+8%0.017-798%
Gross Profit Margin--0.9970.9990%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---2.815--------
Intrinsic Value_10Y_min---5.854--------
Intrinsic Value_1Y_max---0.503--------
Intrinsic Value_1Y_min---0.701--------
Intrinsic Value_3Y_max---1.343--------
Intrinsic Value_3Y_min---2.020--------
Intrinsic Value_5Y_max---1.980--------
Intrinsic Value_5Y_min---3.234--------
Market Cap118162439.500-29%151969462.400110435278.100+38%85637181.630+77%218905111.796-31%425899296.123-64%
Net Profit Margin---907.900-226.975-75%-97410.716+10629%-24662.286+2616%34280.849-103%
Operating Margin---959.100-239.775-75%-35606.904+3613%-12306.012+1183%40765.687-102%
Operating Ratio--960.100240.025+300%36320.842-97%12449.054-92%-87051.062+9167%
Pb Ratio3.076-29%3.9562.345+69%1.763+124%2.010+97%5.397-27%
Pe Ratio-3.254+22%-4.185-3.040-27%-1.945-54%-4.163-1%-10.020+139%
Price Per Share1.835-29%2.3601.715+38%1.330+77%3.399-31%6.614-64%
Price To Free Cash Flow Ratio-3.879+22%-4.989-3.381-32%-2.281-54%-5.016+1%-12.937+159%
Price To Total Gains Ratio-14.528+22%-18.684-10.339-45%-12.704-32%-25.706+38%-30.751+65%
Quick Ratio--6.1406.173-1%6.205-1%10.950-44%13.151-53%
Return On Assets---0.200-0.162-19%-0.274+37%-0.148-26%-0.119-40%
Return On Equity---0.236-0.186-22%-0.326+38%-0.169-28%-0.136-42%
Total Gains Per Share---0.126-0.018-86%-0.150+19%-0.130+3%0.014-1016%
Usd Book Value--38414401.00050486145.750-24%53701569.500-28%104284619.550-63%98201784.800-61%
Usd Book Value Change Per Share---0.126-0.018-86%-0.150+19%-0.130+3%0.014-1016%
Usd Book Value Per Share--0.5970.784-24%0.834-28%1.619-63%1.525-61%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.141-0.143+2%-0.181+29%-0.199+41%-0.153+8%
Usd Free Cash Flow---7615798.000-8725324.250+15%-11635419.750+53%-11519347.700+51%-8683657.775+14%
Usd Free Cash Flow Per Share---0.118-0.135+15%-0.181+53%-0.179+51%-0.135+14%
Usd Free Cash Flow To Equity Per Share---0.118-0.024-80%-0.148+26%-0.127+8%0.017-798%
Usd Market Cap118162439.500-29%151969462.400110435278.100+38%85637181.630+77%218905111.796-31%425899296.123-64%
Usd Price Per Share1.835-29%2.3601.715+38%1.330+77%3.399-31%6.614-64%
Usd Profit---9079000.000-9079648.500+0%-16329692.420+80%-13699188.334+51%-10281002.192+13%
Usd Revenue--10000.0002500.000+300%18768.750-47%570410.900-98%2629508.900-100%
Usd Total Gains Per Share---0.126-0.018-86%-0.150+19%-0.130+3%0.014-1016%
 EOD+3 -5MRQTTM+12 -22YOY+25 -95Y+18 -1610Y+9 -25

4.2. Fundamental Score

Let's check the fundamental score of GlycoMimetics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.254
Price to Book Ratio (EOD)Between0-13.076
Net Profit Margin (MRQ)Greater than0-907.900
Operating Margin (MRQ)Greater than0-959.100
Quick Ratio (MRQ)Greater than16.140
Current Ratio (MRQ)Greater than16.407
Debt to Asset Ratio (MRQ)Less than10.152
Debt to Equity Ratio (MRQ)Less than10.180
Return on Equity (MRQ)Greater than0.15-0.236
Return on Assets (MRQ)Greater than0.05-0.200
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of GlycoMimetics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5029.458
Ma 20Greater thanMa 502.514
Ma 50Greater thanMa 1002.751
Ma 100Greater thanMa 2002.663
OpenGreater thanClose1.800
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets45,316
Total Liabilities6,902
Total Stockholder Equity38,414
 As reported
Total Liabilities 6,902
Total Stockholder Equity+ 38,414
Total Assets = 45,316

Assets

Total Assets45,316
Total Current Assets43,791
Long-term Assets1,526
Total Current Assets
Cash And Cash Equivalents 41,793
Net Receivables 176
Other Current Assets 1,822
Total Current Assets  (as reported)43,791
Total Current Assets  (calculated)43,791
+/-0
Long-term Assets
Property Plant Equipment 768
Long-term Assets Other 758
Long-term Assets  (as reported)1,526
Long-term Assets  (calculated)1,526
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities6,835
Long-term Liabilities67
Total Stockholder Equity38,414
Total Current Liabilities
Short-term Debt 742
Accounts payable 868
Other Current Liabilities 5,226
Total Current Liabilities  (as reported)6,835
Total Current Liabilities  (calculated)6,835
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt67
Long-term Liabilities  (as reported)67
Long-term Liabilities  (calculated)67
+/- 0
Total Stockholder Equity
Common Stock64
Retained Earnings -456,485
Other Stockholders Equity 494,835
Total Stockholder Equity (as reported)38,414
Total Stockholder Equity (calculated)38,414
+/-0
Other
Capital Stock64
Cash and Short Term Investments 41,793
Common Stock Shares Outstanding 64,394
Liabilities and Stockholders Equity 45,316
Net Debt -40,984
Net Invested Capital 38,414
Net Working Capital 36,956
Property Plant and Equipment Gross 768
Short Long Term Debt Total 808



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302011-12-31
> Total Assets 
28,909
0
18,420
0
11,554
9,561
5,283
58,064
67,520
62,432
57,264
48,461
62,045
55,742
48,462
40,701
55,771
48,011
42,388
37,174
121,622
115,822
128,583
247,421
235,696
225,170
214,839
204,442
192,335
180,455
167,970
162,099
158,353
150,419
142,832
138,020
124,379
107,945
94,347
81,465
65,044
55,961
51,811
68,922
61,822
53,201
45,316
45,31653,20161,82268,92251,81155,96165,04481,46594,347107,945124,379138,020142,832150,419158,353162,099167,970180,455192,335204,442214,839225,170235,696247,421128,583115,822121,62237,17442,38848,01155,77140,70148,46255,74262,04548,46157,26462,43267,52058,0645,2839,56111,554018,420028,909
   > Total Current Assets 
0
0
17,969
0
11,137
9,137
4,884
57,685
67,099
61,950
56,115
47,344
60,769
54,478
47,244
39,513
54,534
46,522
40,520
35,288
119,650
113,888
127,220
246,109
232,918
222,434
212,269
198,390
186,469
174,797
162,528
156,882
153,358
145,643
138,273
133,709
120,315
104,134
90,255
77,464
61,264
53,848
50,715
68,087
60,369
52,010,075
43,791
43,79152,010,07560,36968,08750,71553,84861,26477,46490,255104,134120,315133,709138,273145,643153,358156,882162,528174,797186,469198,390212,269222,434232,918246,109127,220113,888119,65035,28840,52046,52254,53439,51347,24454,47860,76947,34456,11561,95067,09957,6854,8849,13711,137017,96900
       Cash And Cash Equivalents 
28,172
0
17,373
0
10,778
7,690
2,311
56,966
66,217
61,362
55,199
46,567
40,234
53,760
46,803
38,830
53,085
45,283
40,042
34,591
119,148
112,873
123,925
242,632
229,435
219,829
209,918
195,561
184,167
170,887
158,201
154,823
149,845
142,870
137,035
132,471
118,854
101,924
90,255
76,516
60,244
51,625
47,871
65,002
58,037
49,408
41,793
41,79349,40858,03765,00247,87151,62560,24476,51690,255101,924118,854132,471137,035142,870149,845154,823158,201170,887184,167195,561209,918219,829229,435242,632123,925112,873119,14834,59140,04245,28353,08538,83046,80353,76040,23446,56755,19961,36266,21756,9662,3117,69010,778017,373028,172
       Short-term Investments 
73
0
83
0
0
83
83
83
83
58
58
58
57
57
9
0
0
0
11
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000001100095757585858838383830083073
       Net Receivables 
0
0
0
0
0
0
0
0
42
0
22
1
20,001
1
39
59
612
572
269
41
68
76
102
153
326
312
413
354
313
579
186
92
49
2
2
445
2
1
1
5
121
90
144
234
215
189
176
1761892152341449012151124452249921865793133544133123261531027668412695726125939120,00112204200000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
762
521
706
393
618
836
0
199
651
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-535
0
0
0
-144
-3,081,339
-2,329,646
49,358,032
0
049,358,032-2,329,646-3,081,339-144000-535000000000000000000651199083661839370652176200000000000
   > Long-term Assets 
0
0
451
0
417
423
400
379
421
482
1,149
1,117
1,276
1,264
1,218
1,188
1,237
1,488
1,868
1,886
1,971
1,934
1,364
1,311
2,778
2,736
2,570
6,052
5,866
5,658
5,442
5,218
4,995
4,776
4,559
4,311
4,064
3,811
4,092
4,001
3,780
2,113
1,096
835
1,453
1,190,609
1,526
1,5261,190,6091,4538351,0962,1133,7804,0014,0923,8114,0644,3114,5594,7764,9955,2185,4425,6585,8666,0522,5702,7362,7781,3111,3641,9341,9711,8861,8681,4881,2371,1881,2181,2641,2761,1171,149482421379400423417045100
       Property Plant Equipment 
235
0
451
0
417
423
400
379
421
482
452
420
579
567
521
491
488
677
1,056
1,075
1,160
1,122
1,107
1,055
1,010
969
957
4,439
4,253
4,045
3,829
3,605
3,382
3,163
2,946
2,698
2,451
2,198
1,945
1,727
1,507
1,253
994
733
1,350
1,088,289
768
7681,088,2891,3507339941,2531,5071,7271,9452,1982,4512,6982,9463,1633,3823,6053,8294,0454,2534,4399579691,0101,0551,1071,1221,1601,0751,05667748849152156757942045248242137940042341704510235
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
697
697
697
697
697
697
749
812
812
812
812
812
257
257
1,767
1,767
1,613
1,613
1,613
1,613
1,613
1,613
1,613
1,613
1,613
1,613
1,613
1,613
2,147
2,274
2,274
860
102
102
102
102,320
758
758102,3201021021028602,2742,2742,1471,6131,6131,6131,6131,6131,6131,6131,6131,6131,6131,6131,6131,7671,7672572578128128128128127496976976976976976970000000000
> Total Liabilities 
20,452
0
5,891
0
1,815
3,046
2,376
2,710
3,636
4,723
6,461
4,104
6,825
7,037
7,990
5,933
6,894
6,259
7,087
5,288
6,190
7,258
8,882
9,382
7,701
7,074
9,375
11,648
13,776
13,374
13,769
13,609
12,600
12,153
14,613
12,896
12,092
11,379
12,743
13,434
9,317
7,844
8,881
6,740
7,021
6,653
6,902
6,9026,6537,0216,7408,8817,8449,31713,43412,74311,37912,09212,89614,61312,15312,60013,60913,76913,37413,77611,6489,3757,0747,7019,3828,8827,2586,1905,2887,0876,2596,8945,9337,9907,0376,8254,1046,4614,7233,6362,7102,3763,0461,81505,891020,452
   > Total Current Liabilities 
16,412
0
5,692
0
1,666
2,922
2,279
2,642
3,597
4,714
6,461
4,104
6,797
6,850
7,747
5,683
6,095
5,418
6,334
4,534
5,447
6,531
8,175
8,696
7,037
6,434
8,763
8,307
10,633
10,436
10,951
10,612
9,701
9,818
12,428
10,842
10,249
9,660
11,824
12,782
8,938
7,748
8,881
6,740
6,572
6,390,880
6,835
6,8356,390,8806,5726,7408,8817,7488,93812,78211,8249,66010,24910,84212,4289,8189,70110,61210,95110,43610,6338,3078,7636,4347,0378,6968,1756,5315,4474,5346,3345,4186,0955,6837,7476,8506,7974,1046,4614,7143,5972,6422,2792,9221,66605,692016,412
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
740
761
784
804
827
850
874
899
923
949
975
1,001
1,029
1,056
1,084
919
652
820
749,618
742
742749,6188206529191,0841,0561,0291,001975949923899874850827804784761740000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
740
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000740000000000000000000000000000
       Accounts payable 
535
0
764
0
539
1,754
1,145
1,797
472
584
874
1,183
1,107
633
564
1,623
1,397
1,247
1,565
512
575
1,632
2,647
3,854
3,240
659
2,664
1,867
3,027
1,408
1,436
3,134
1,371
1,074
2,090
2,141
1,175
1,390
2,108
2,276
1,271
852
970
480
241
329,885
868
868329,8852414809708521,2712,2762,1081,3901,1752,1412,0901,0741,3713,1341,4361,4083,0271,8672,6646593,2403,8542,6471,6325755121,5651,2471,3971,6235646331,1071,1838745844721,7971,1451,75453907640535
       Other Current Liabilities 
15,877
0
935
0
997
1,091
1,134
845
3,125
4,130
5,587
2,920
5,690
6,217
7,183
4,061
4,697
4,171
4,768
4,022
4,872
4,899
5,528
4,842
3,798
5,775
6,100
740
6,845
8,245
8,711
6,651
7,480
7,871
9,440
7,778
8,126
7,295
7,797
9,477
6,611
5,812
6,992
5,608
5,510,272
5,311,377
5,226
5,2265,311,3775,510,2725,6086,9925,8126,6119,4777,7977,2958,1267,7789,4407,8717,4806,6518,7118,2456,8457406,1005,7753,7984,8425,5284,8994,8724,0224,7684,1714,6974,0617,1836,2175,6902,9205,5874,1303,1258451,1341,0919970935015,877
   > Long-term Liabilities 
0
0
200
0
149
124
97
68
39
10
0
0
28
187
244
250
799
841
754
754
743
727
707
686
664
640
612
3,341
3,143
2,937
2,819
2,997
2,899
2,335
2,184
2,054
1,843
1,719
919
652
379
96
1,889
1,131,885
449
262,133
67
67262,1334491,131,8851,889963796529191,7191,8432,0542,1842,3352,8992,9972,8192,9373,1433,341612640664686707727743754754841799250244187280010396897124149020000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,341
3,143
2,937
2,819
2,604
2,384
2,155
1,920
1,680
1,435
1,180
919
652
379
96
0
0
449
-748,606
67
67-748,60644900963796529191,1801,4351,6801,9202,1552,3842,6042,8192,9373,1433,341000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,341
3,143
2,937
2,819
2,997
2,899
2,335
2,184
2,054
1,843
0
0
0
0
96
0
0
449
0
0
00449009600001,8432,0542,1842,3352,8992,9972,8192,9373,1433,341000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
68
39
10
0
0
28
187
244
250
799
841
754
754
743
727
707
686
664
640
612
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000061264066468670772774375475484179925024418728001039680000000
> Total Stockholder Equity
8,457
0
12,528
0
9,738
6,515
2,907
55,354
63,884
57,708
50,803
44,357
55,220
48,705
40,472
34,768
48,877
41,751
35,301
31,886
115,432
108,564
119,701
238,039
227,995
218,096
205,464
192,794
178,559
167,081
154,201
148,490
145,752
138,266
128,219
125,124
112,286
96,566
81,604
68,031
55,727
48,118
42,930
62,181
54,801
46,548
38,414
38,41446,54854,80162,18142,93048,11855,72768,03181,60496,566112,286125,124128,219138,266145,752148,490154,201167,081178,559192,794205,464218,096227,995238,039119,701108,564115,43231,88635,30141,75148,87734,76840,47248,70555,22044,35750,80357,70863,88455,3542,9076,5159,738012,52808,457
   Common Stock
1
0
10
0
3
11
1
19
19
19
19
19
19
19
19
19
23
23
23
24
33
33
34
42
43
43
43
43
43
43
43
44
47
48
49
52
52
52
52
52
52
52
54
64
64
64,369
64
6464,3696464545252525252525249484744434343434343434234333324232323191919191919191919111301001
   Retained Earnings Total Equity
0
0
0
0
0
0
0
68,377
-60,386
-67,003
-74,397
-81,506
-71,117
-78,285
-87,166
-94,721
-102,793
-110,648
-118,976
-126,927
-135,069
-143,019
-152,277
-163,790
-175,069
-186,644
-200,551
-214,635
-230,464
-243,716
-258,443
-266,105
-280,184
-293,907
-309,470
-323,744
-338,143
0
0
0
0
-409,341
0
-429,945
-438,204
0
0
00-438,204-429,9450-409,3410000-338,143-323,744-309,470-293,907-280,184-266,105-258,443-243,716-230,464-214,635-200,551-186,644-175,069-163,790-152,277-143,019-135,069-126,927-118,976-110,648-102,793-94,721-87,166-78,285-71,117-81,506-74,397-67,003-60,38668,3770000000
   Accumulated Other Comprehensive Income 0000000000-2,194-2,1260-2,064-1,997-1,930-1,862-1,794-1,724-1,654-1,584-1,515-1,447-1,378-1,309-1,251-1,180-1,111-1,057-1,036-996-949-902-853-996-950-905-866-825-791-756-745-8610-79600
   Capital Surplus 
0
0
0
0
0
0
0
123,713
124,250
124,693
125,181
125,844
126,318
126,971
127,619
129,470
151,647
152,376
154,254
158,790
250,468
251,551
271,944
401,787
403,021
404,696
405,972
407,385
408,980
410,754
412,600
414,552
425,890
432,125
437,640
448,816
450,378
0
0
0
0
457,407
0
492,062
492,940
0
0
00492,940492,0620457,4070000450,378448,816437,640432,125425,890414,552412,600410,754408,980407,385405,972404,696403,021401,787271,944251,551250,468158,790154,254152,376151,647129,470127,619126,971126,318125,844125,181124,693124,250123,7130000000
   Treasury Stock00000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
65,984
0
66,262
66,657
66,907
124,503
125,075
125,558
126,087
126,794
127,314
127,824
128,521
130,419
152,643
153,412
155,311
159,901
251,649
252,802
273,254
403,165
404,467
406,212
407,556
409,039
410,704
412,548
414,461
416,482
427,887
434,189
437,640
450,942
452,572
451,989
454,449
455,529
456,493
457,407
462,461
492,062
492,940
447,388,751
494,835
494,835447,388,751492,940492,062462,461457,407456,493455,529454,449451,989452,572450,942437,640434,189427,887416,482414,461412,548410,704409,039407,556406,212404,467403,165273,254252,802251,649159,901155,311153,412152,643130,419128,521127,824127,314126,794126,087125,558125,075124,50366,90766,65766,262065,98400



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue10
Cost of Revenue-153
Gross Profit-143-143
 
Operating Income (+$)
Gross Profit-143
Operating Expense-39,132
Operating Income-39,275-39,275
 
Operating Expense (+$)
Research Development20,072
Selling General Administrative19,213
Selling And Marketing Expenses-19,194,577
Operating Expense39,132-19,155,292
 
Net Interest Income (+$)
Interest Income2,242
Interest Expense-0
Other Finance Cost-0
Net Interest Income2,242
 
Pretax Income (+$)
Operating Income-39,275
Net Interest Income2,242
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-36,899-41,651
EBIT - interestExpense = -39,275
-36,899
-36,899
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-39,275-36,899
Earnings Before Interest and Taxes (EBITDA)-39,122
 
After tax Income (+$)
Income Before Tax-36,899
Tax Provision-0
Net Income From Continuing Ops-38,064-36,899
Net Income-36,899
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses39,285
Total Other Income/Expenses Net2,376-2,242
 

Technical Analysis of Glycomimetics
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Glycomimetics. The general trend of Glycomimetics is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Glycomimetics's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of GlycoMimetics Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 2.2 < 3.18 < 3.38.

The bearish price targets are: 1.77 > 1.74 > 1.74.

Tweet this
GlycoMimetics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of GlycoMimetics Inc. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

GlycoMimetics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of GlycoMimetics Inc. The current macd is -0.25054616.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Glycomimetics price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Glycomimetics. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Glycomimetics price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
GlycoMimetics Inc Daily Moving Average Convergence/Divergence (MACD) ChartGlycoMimetics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of GlycoMimetics Inc. The current adx is 30.92.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Glycomimetics shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
GlycoMimetics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of GlycoMimetics Inc. The current sar is 2.27521168.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
GlycoMimetics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of GlycoMimetics Inc. The current rsi is 29.46. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 2/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending up: The RSI is trending up. +1
GlycoMimetics Inc Daily Relative Strength Index (RSI) ChartGlycoMimetics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of GlycoMimetics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Glycomimetics price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
GlycoMimetics Inc Daily Stochastic Oscillator ChartGlycoMimetics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of GlycoMimetics Inc. The current cci is -150.6642584.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
GlycoMimetics Inc Daily Commodity Channel Index (CCI) ChartGlycoMimetics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of GlycoMimetics Inc. The current cmo is -50.49254849.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
GlycoMimetics Inc Daily Chande Momentum Oscillator (CMO) ChartGlycoMimetics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of GlycoMimetics Inc. The current willr is -91.51785714.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
GlycoMimetics Inc Daily Williams %R ChartGlycoMimetics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of GlycoMimetics Inc.

GlycoMimetics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of GlycoMimetics Inc. The current atr is 0.21896411.

GlycoMimetics Inc Daily Average True Range (ATR) ChartGlycoMimetics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of GlycoMimetics Inc. The current obv is 18,158,898.

GlycoMimetics Inc Daily On-Balance Volume (OBV) ChartGlycoMimetics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of GlycoMimetics Inc. The current mfi is 15.64.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
GlycoMimetics Inc Daily Money Flow Index (MFI) ChartGlycoMimetics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for GlycoMimetics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-01BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-13BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-18MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-16RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-30WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-11BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-19BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

GlycoMimetics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of GlycoMimetics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5029.458
Ma 20Greater thanMa 502.514
Ma 50Greater thanMa 1002.751
Ma 100Greater thanMa 2002.663
OpenGreater thanClose1.800
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Glycomimetics with someone you think should read this too:
  • Are you bullish or bearish on Glycomimetics? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Glycomimetics? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about GlycoMimetics Inc

I send you an email if I find something interesting about GlycoMimetics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about GlycoMimetics Inc.

Receive notifications about GlycoMimetics Inc in your mailbox!